1339P Efficacy and safety of MIL60, a bevacizumab biosimilar, in combination with paclitaxel/carboplatin in patients with advanced or recurrent non-squamous non-small cell lung cancer: A randomized, double-blind, multicenter phase III study

• DOI: 10.1016/j.annonc.2021.08.1940
• Publication Date: 2021-09-21T22:22:15Z
• Authors: J. Wang; R. Wang; X. Dong; Q. Chen; Y. Yu; S. Yang; X. Zhang; G. Zhang; Y. Pan; S. Sun; C. Zhou; W. Hong; H. Zhao; L. Yang; L. Huang; R. Wu; A. Zang; R. Ma; L. Wu; D. Lv
• Keywords: Biosimilar; Carboplatin